biostudies-literatureLillie PJMedical Research CouncilWellcome Trust19-25https://www.ebi.ac.uk/biostudies/studies/S-EPMC3369564biostudies-literatureUnknown55(1)<h4>Background</h4>The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers.<h4>Methods</h4>Volunteers with no measurable serum antibodies to influenza A/Wisconsin/67/2005 received either a single vaccination with MVA-NP+M1 or no vaccination. T-cell responses to the vaccine antigens were measured at enrollment and again prior to virus challenge. All volunteers underwent intranasal admiClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPreliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.PMC3369564095540G1001046G0600520081865090532Peng YDong TLambe TSheehy SHHill AVBlais MEGilbert AOxford JGilbert SCSpencer AJHamill MDuncan CJHavelock TPowell TJLillie PJWilliams RLMullarkey CBerthoud TKFaust SNfalsePreliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.<h4>Background</h4>The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers.<h4>Methods</h4>Volunteers with no measurable serum antibodies to influenza A/Wisconsin/67/2005 received either a single vaccination with MVA-NP+M1 or no vaccination. T-cell responses to the vaccine antigens were measured at enrollment and again prior to virus challenge. All volunteers underwent intranasal admi2012-01-01T00:00:00Z2012 Jul2026-05-04T20:53:30.618Z2019-03-27T00:54:15ZS-EPMC33695642244165010.1093/cid/cis327